Swedish biotech Oxcia has promoted Dr. Sandra Ekstedt to Preclinical Director to advance the development of OXC-201, a first-in-class oral inhibitor targeting the OGG1 enzyme. The drug candidate is designed to treat Idiopathic Pulmonary Fibrosis (IPF) by blocking the interaction between damaged DNA and OGG1, thereby preventing inflammation and fibrosis. Dr. Ekstedt, a specialist in respiratory diseases, will finalize the preclinical program and investigate the drug's ability to alleviate cough and improve lung function.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.